Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Astrazeneca

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Astrazeneca

1 Apr 2019 18:00

RNS Number : 7122U
FTSE Russell
01 April 2019
 

 

 

 

 

AstraZeneca (UK): Shares in Issue ChangeChanges in FTSE UK Index Series

01 April 2019

Following the receipt of updated shares in issue information for AstraZeneca (UK, constituent) as a result of a primary placing, please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE 100 Index

04 April 2019

FTSE 350 Index

04 April 2019

FTSE All-Share Index

04 April 2019

FTSE 350 Higher Yield Index

04 April 2019

Techmark All Share Index

04 April 2019

 

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSSSDFDFFUSEEL
12345678910
Date   Source Headline
22nd Dec 202511:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:30 amRNSEnhertu granted BTD for post-neoadjuvant early BC
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
22nd Dec 20257:00 amRNSUpdate on LATIFY Phase III trial of ceralasertib
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
16th Dec 20257:05 amRNSSubcutaneous Saphnelo approved in EU
16th Dec 20257:00 amRNSEnhertu approved in US for 1L HER2+ metastatic BC
4th Dec 20253:00 pmRNSHolding(s) in Company
1st Dec 20253:05 pmRNSBlock listing Interim Review
1st Dec 20253:00 pmRNSTotal Voting Rights
26th Nov 20257:00 amRNSImfinzi approved in US for early gastric cancer
24th Nov 20257:00 amRNSAstraZeneca manufacturing investment in Maryland
20th Nov 20257:00 amRNSKoselugo (selumetinib) approved in the US
17th Nov 20253:00 pmRNSHolding(s) in Company
14th Nov 202511:00 amRNSDirector/PDMR Shareholding
10th Nov 20253:00 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNS9M and Q3 2025 results
3rd Nov 20254:00 pmRNSResult of General Meeting
3rd Nov 20253:00 pmRNSTotal Voting Rights
28th Oct 20257:05 amRNSDirector Declaration
28th Oct 20257:00 amRNSKoselugo (selumetinib) approved in the EU
22nd Oct 20257:00 amRNSTezspire Approved in EU for CRSwNP
20th Oct 20257:05 amRNSUS FDA Approves Tezspire in CRSwNP
20th Oct 20257:00 amRNSPositive CHMP opinion for subcutaneous Saphnelo
13th Oct 20257:00 amRNSAgreement with US Govt to lower medicine prices
7th Oct 20257:00 amRNSBaxdrostat met primary endpoint in Bax24 Ph3 trial
6th Oct 20257:30 amRNSDatroway improved OS and PFS in TROPION-Breast02
1st Oct 20253:00 pmRNSTotal Voting Rights
29th Sep 20257:30 amRNSEnhertu improved IDFS in early BC in DB-05
29th Sep 20257:00 amRNSAZN harmonises listing structure
25th Sep 20254:30 pmRNSDirector/PDMR Shareholding
22nd Sep 20257:05 amRNSKoselugo recommended for EU approval
22nd Sep 20257:00 amRNSTezspire Recommended for Approval in EU for CRSwNP
17th Sep 20257:05 amRNSSaphnelo met primary endpoint in TULIP-SC
17th Sep 20257:00 amRNSUpdate on RESOLUTE Phase III trial
1st Sep 20253:00 pmRNSTotal Voting Rights
28th Aug 20253:00 pmRNSHolding(s) in Company
26th Aug 20253:00 pmRNSHolding(s) in Company
21st Aug 20253:00 pmRNSHolding(s) in Company
18th Aug 20253:00 pmRNSDirector/PDMR Shareholding
15th Aug 20253:00 pmRNSHolding(s) in Company
12th Aug 20253:00 pmRNSHolding(s) in Company
1st Aug 20253:00 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSH1 and Q2 2025 results
24th Jul 20257:00 amRNSGefurulimab nanobody met Phase III endpoints
22nd Jul 20257:00 amRNSAstraZeneca plans to invest $50bn in the US
16th Jul 20257:00 amRNSUpdate on anselamimab in AL amyloidosis
14th Jul 20257:00 amRNSBaxdrostat met primary endpt in BaxHTN PhIII trial
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
SOI
Schroders
LSE
-3.56%
SHRS
Shires Inc.
LSE
0.00%
HOME
Home Reit
LSE
-1.83%
PREM
Premier African Minerals
LSE
9.52%
HHV
Hargreave
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
PPP
Pennpetro Energy
LSE
0.00%
GST
GSTechnologies
LSE
8.11%
NANO
Nanoco
LSE
-10.69%
LLOY
Lloyds
LSE
-1.33%